FDA approves GSK hepatitis B therapy with broader cure reach
The FDA has approved a GSK hepatitis B medicine that helped far more patients achieve a functional cure than prior options.
The FDA has approved a GSK medicine for hepatitis B, a viral infection that can affect the liver. The decision adds a new treatment option for clinicians and patients to consider.
The available summary says the therapy helped substantially more patients reach a functional cure than earlier choices. That comparative result is the key claim provided; details on trial size, patient groups, and safety are not included.
For people living with hepatitis B and their clinicians, the approval may add a treatment conversation centered on functional cure. If the broader cure reach described in the summary holds in practice, more patients could have a chance at that outcome. Real-world benefit may depend on access, cost, and follow-up, so the societal effect could vary across health systems and patient groups.